Examples of 'population pharmacokinetic' in a sentence
Meaning of "population pharmacokinetic"
population pharmacokinetic: This phrase is a term used in pharmacology to describe the study of variations in drug concentration in a population
How to use "population pharmacokinetic" in a sentence
Basic
Advanced
population pharmacokinetic
In vivo studies and population pharmacokinetic analysis.
A population pharmacokinetic analysis has been conducted on a group of.
This was confirmed using a population pharmacokinetic model.
Population pharmacokinetic analysis in special populations.
As demonstrated in specific pharmacokinetic studies and in population pharmacokinetic analyses.
Population pharmacokinetic modelling and simulation at steady state.
The data presented in this paragraph are based on a population pharmacokinetic analysis.
Paediatric population pharmacokinetic study.
Approximately linear pharmacokinetics is observed at steady state in the population pharmacokinetic studies.
A population pharmacokinetic analysis showed no effect of age on pharmacokinetics of plerixafor.
The effect of race on doripenem pharmacokinetics was examined through a population pharmacokinetic analysis.
A population pharmacokinetic analysis showed no effect of gender on pharmacokinetics of plerixafor.
The effect of age on the pharmacokinetics of atezolizumab was assessed in a population pharmacokinetic analysis.
Based on population pharmacokinetic analyses.
Age did not affect belimumab exposure in the subcutaneous population pharmacokinetic analysis.
See also
Population pharmacokinetic data derived from studies in dogs with a predominately.
Age is not a significant covariate in the population pharmacokinetic analysis of patients with acromegaly.
Population pharmacokinetic analysis.
The pharmacokinetics of caplacizumab were determined using a population pharmacokinetic analysis on pooled pharmacokinetic data.
A population pharmacokinetic modelling approach was used to investigate the influence of covariates.
The effect of mild or moderate renal impairment was evaluated using a population pharmacokinetic model.
Population pharmacokinetic ol.
Body weight did not have a significant effect on sofosbuvir exposure according to a population pharmacokinetic analysis.
Population pharmacokinetic modelling indicated that exposure decreased as body weight increased.
Pharmacokinetic data from all asfotase alfa clinical trials were analysed using population pharmacokinetic methods.
A population pharmacokinetic analysis did not find significant influence of renal function creatinine clearance.
Gender was not identified as a statistically significant covariate in the Population Pharmacokinetic Analysis of tapentadol.
A population pharmacokinetic analysis was performed to evaluate the effects of demographic characteristics on blinatumomab pharmacokinetics.
Race had no effect on the pharmacokinetics of peginterferon beta-1a in a population pharmacokinetic analysis.
Analysis of patient population pharmacokinetic data did not show a relevant effect of age on pharmacokinetics.
No gender effect on the pharmacokinetics of peginterferon beta-1a was found in a population pharmacokinetic analysis.
Population pharmacokinetic analysis indicated that gender did not have an effect on brodalumab pharmacokinetics.
Finally, the long-term data from patients were analysed using a population pharmacokinetic approach.
The population pharmacokinetic analysis did not identify race as significantly influencing entecavir pharmacokinetics.
The estimated terminal half-life for a typical patient from the population pharmacokinetic analysis is approximately 1 day.
These population pharmacokinetic studies have the advantage of providing data from the intended patient population.
Based on estimates from the population pharmacokinetic analysis, East Asian i . e.
A population pharmacokinetic analysis has been performed in patients receiving TAXOTERE.
Gender, Gender does not affect the pharmacokinetics of lixisenatide based on a population pharmacokinetic data analysis.
Paediatric population Pharmacokinetic data in paediatric patients are not available.
L / hr in HIV-infected patients based on a population pharmacokinetic analysis.
Population pharmacokinetic analysis was performed with the NONMEM program.
The linear clearance was estimated as a parameter in the population pharmacokinetic analysis and was 12.5 ml / h.
Population pharmacokinetic analysis of Victrelis indicated that race had no apparent effect on exposure.
The mean clearance in pediatric patients estimated by the population pharmacokinetic analysis was 4.7 L / h.
Population pharmacokinetic analysis of Victrelis indicated that age had no apparent effect on exposure.
The apparent volume of distribution was 806 L in cancer patients based on population pharmacokinetic analysis.
Population pharmacokinetic and pharmacodynamic modeling was performed using the software package NONMEM.
Elderly patients ( ≥ 65 years ) Age is not a significant covariate in the population pharmacokinetic analysis of patients.
Paediatric population Pharmacokinetic parameters and the extent of absorption have not been studied in children.
You'll also be interested in:
Examples of using Pharmacokinetic
Show more
The pharmacokinetic genes inform the dosage
There are no marked changes in the pharmacokinetic parameters
Pharmacokinetic interaction studies have not been conducted
Examples of using Population
Show more
Detailed population statistics were provided in the report
Distribution of the employed population by sector of activity
Population displacements had basically economic causes
